CompletedNot Applicable

Probiotics on Immune Function and Intestinal Microbiota in Astronauts Under Closed Microgravity Environment

Japan10 participantsStarted 2015-10

Plain-language summary

Human immune function and intestinal microbiota are suggested to be altered within long-duration stay in space. Accumulated evidences on earth support that Lacticaseibacillus paracasei strain Shirota (LcS) is a promising probiotic strain on improvement of immune function and intestinal microbiota. This study aims to investigate the impact of long-duration spaceflight as well as intake of LcS on the international space station (ISS), on immune system and intestinal microbiota in astronauts.

Who can participate

Age range25 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Individuals who are scheduled to stay on the ISS for at least 3 months * Individuals who fully understand the study protocol and provide written informed consent for the study participation Exclusion Criteria: * Individuals who routinely use antibiotic, laxative, and/or bowel regulating medicine * Individuals who participate in other research that competes with this study in terms of the purpose and field, e.g., study with dietary management or intake of bifidobacteria/lactic acid bacteria, oligosaccharides, antibiotic, laxative, and/or bowel regulating medicine

What they're measuring

Longitudinal changes in the number of LcS in feces

Timeframe: 9-18 months

Longitudinal changes in the level of immune markers

Timeframe: 9-18 months

Longitudinal changes in numbers and composition of intestinal microbiota

Timeframe: 9-18 months

Trial details

NCT IDNCT02618005

SponsorYakult Honsha Co., LTD

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-04

View on ClinicalTrials.gov More Immune Function and Intestinal Microbiota trials